Results 131 to 140 of about 189,617 (226)

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Centralni portal znanstvenih časopisa Hrvatske - HRCAK [PDF]

Kemija u Industriji, 2006
Tóth, T.
doaj  

Editorial Self-Publication in Scientific Journals: Insights and Implications for Otorhinolaryngology Practice. [PDF]

Turk Arch Otorhinolaryngol
Bayram A.
europepmc   +1 more source

The "Great Family" of Cardiovascular Scientific Journals in Brazil. [PDF]

Braz J Cardiovasc Surg, 2020
Evora PRB.
europepmc   +1 more source

Conflicts of interest are harming maternal and child health: time for scientific journals to end relationships with manufacturers of breast-milk substitutes. [PDF]

BMJ Glob Health, 2022
Pereira-Kotze C, Jeffery B, Badham J, Swart EC, du Plessis L, Goga A, Lake L, Kroon M, Saloojee H, Scott C, Mercer R, Waterston T, Goldhagen J, Clark D, Baker P, Doherty T.   +15 more
europepmc   +1 more source

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

Arthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

The incentive for innovation and the scientific journals: Could there be conflicts of interest? [PDF]

Arq Bras Oftalmol
Kara-Junior N.
europepmc   +1 more source

The Role of IgM Anti‐acetylated Protein Antibodies and B Cells in the Origin of Antimodified Protein Autoimmunity in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) is characterized by anti‐modified protein antibodies (AMPAs), including anti‐citrullinated protein antibodies (ACPA), anti‐carbamylated protein antibodies (anti‐CarP), and anti‐acetylated protein antibodies (AAPA). In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role ...
Aegli Athanasiadou, Sanne Kroos, Renee van de Wetering, Rian Schopmeijer, Carin van der Keur, Michael Eikmans, Caroline Meijer, Solbritt Rantapää‐Dahlqvist, René E. M. Toes, Linda M. Slot, Diane van der Woude   +10 more
wiley   +1 more source

Forest@: a new journal for forest and environmental science

Forest@, 2004
Borghetti M
doaj   +1 more source